ProCE Banner Activity

Expert Guidance for the Treatment of CLL: An International Perspective

Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with CLL with those of 5 renowned international experts, from Clinical Care Options.

Released: February 08, 2024

Share

Faculty

Florence Cymbalista

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

Toby Eyre

Toby Eyre, MBChB, MD

Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Carsten Niemann

Carsten Niemann, MD

Consultant in Hematology: Internal Medicine
Rigshospitalet, Copenhagen University Hospital
Department of Hematology
Copenhagen, Denmark

Stephan Stilgenbauer

Stephan Stilgenbauer, MD

Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany

Alessandra Tedeschi

Alessandra Tedeschi, MD

Director of Indolent Lymphoproliferative Disorders
Department of Hematology
Niguarda Cancer Center
Niguarda Hospital
Milan, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Disclosure

Primary Author

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

Florence Cymbalista, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Beigene, Janssen, Lilly.

Toby Eyre, MBChB, MD

Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Toby Eyre, MBCHB, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Autolus, Beigene, Incyte, Janssen, Kite/Gilead, Lilly, Roche, Secura Bio; researcher: AstraZeneca, Beigene.

Carsten Niemann, MD

Consultant in Hematology: Internal Medicine
Rigshospitalet, Copenhagen University Hospital
Department of Hematology
Copenhagen, Denmark

Carsten U. Niemann, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Behring, Beigene, CSL, Genmab, Janssen, Lilly, MSD, Octapharma, Takeda. 

Stephan Stilgenbauer, MD

Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany

Stephan Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem; research support: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem. 

Alessandra Tedeschi, MD

Director of Indolent Lymphoproliferative Disorders
Department of Hematology
Niguarda Cancer Center
Niguarda Hospital
Milan, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Beigene, Janssen, Lilly.